{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T18:20:52Z","timestamp":1773685252628,"version":"3.50.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2017,8,7]],"date-time":"2017-08-07T00:00:00Z","timestamp":1502064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The purpose of this study was to evaluate the capacity of 6-mercaptopurine (6-MP), a known immunosuppressant, to normalize cerebrospinal fluid (CSF) lymphocyte frequencies in opsoclonus\u2013myoclonus syndrome (OMS) and function as a steroid sparer. CSF and blood lymphocytes were immunophenotyped in 11 children with OMS (without CSF B cell expansion) using a comprehensive panel of cell surface adhesion, activation and maturation markers by flow cytometry, and referenced to 18 paediatric controls. Drug metabolites, lymphocyte counts and liver function tests were used clinically to monitoring therapeutic range and toxicity. In CSF, adjunctive oral 6-MP was associated with a 21% increase in the low percentage of CD4+ T cells in OMS, restoring the CD4\/CD8 ratio. The percentage of CD4+ T cells that were interferon (IFN)-\u03b3+ was reduced by 66%, shifting the cytokine balance away from T helper type 1 (Th1) (proinflammatory) predominance. The percentage of natural killer (NK) cells decreased significantly in CSF (\u201332%) and blood (\u201367 to \u221282%). Low blood absolute lymphocyte count was more predictive of improvement in CSF lymphocyte proportions (correlated with % CD4+ T cells) than the 6-thioguanine level (no correlation). 6-MP was difficult to titrate: 50% achieved the target absolute lymphocyte count (&amp;lt;\u00a01\u00b75 K\/mm); 20%, the \u2018therapeutic\u2019 6-thioguanine level; and 40% the non-toxic 6-methylmercaptopurine level. Side effects and transaminase elevation were mild and reversible. Clinical steroid-sparing properties and lowered relapse frequency were demonstrated. 6-MP displayed unique pharmacodynamic properties that may be useful in OMS and other autoimmune disorders. Its steroid sparer capacity is limited to children in whom the therapeutic window can be reached without limiting pharmacokinetic factors or side effects.<\/jats:p>","DOI":"10.1111\/cei.13015","type":"journal-article","created":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T15:26:38Z","timestamp":1500132398000},"page":"217-225","source":"Crossref","is-referenced-by-count":10,"title":["6-Mercaptopurine modifies cerebrospinal fluid T cell abnormalities in paediatric opsoclonus\u2013myoclonus as steroid sparer"],"prefix":"10.1093","volume":"190","author":[{"given":"M R","family":"Pranzatelli","sequence":"first","affiliation":[{"name":"National Pediatric Neuroinflammation Organization, Inc., the National Pediatric Myoclonus Center, Orlando, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E D","family":"Tate","sequence":"additional","affiliation":[{"name":"National Pediatric Neuroinflammation Organization, Inc., the National Pediatric Myoclonus Center, Orlando, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T J","family":"Allison","sequence":"additional","affiliation":[{"name":"National Pediatric Neuroinflammation Organization, Inc., the National Pediatric Myoclonus Center, Orlando, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,8,7]]},"reference":[{"key":"2021120808113534200_cei13015-bib-0001","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.braindev.2015.11.007","article-title":"Trends and tenets in relapsing and progressive pediatric opsoclonus-myoclonus","volume":"38","author":"Pranzatelli","year":"2016","journal-title":"Brain Dev"},{"key":"2021120808113534200_cei13015-bib-0002","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.62.9.1526","article-title":"B- and T-cell markers in pediatric opsoclonus\u2013myoclonus syndrome: immunophenotyping of CSF lymphocytes","volume":"62","author":"Pranzatelli","year":"2004","journal-title":"Neurology"},{"key":"2021120808113534200_cei13015-bib-0003","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10875-009-9335-3","article-title":"Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus","volume":"30","author":"Pranzatelli","year":"2010","journal-title":"J Clin Immunol"},{"key":"2021120808113534200_cei13015-bib-0004","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/1043454204272560","article-title":"Neuroepidemiologic trends in 105 U.S. cases of pediatric opsoclonus-myoclonus","volume":"22","author":"Tate","year":"2005","journal-title":"J Pediatr Oncol Nurs"},{"key":"2021120808113534200_cei13015-bib-0005","first-page":"21","article-title":"The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease","volume":"39","author":"Glazier","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"2021120808113534200_cei13015-bib-0006","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2002-08-2372","article-title":"Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92","volume":"102","author":"Harms","year":"2003","journal-title":"Blood"},{"key":"2021120808113534200_cei13015-bib-0007","first-page":"RA247","article-title":"Reviewing the mechanism of action of thiopurine drugs: toward a new paradigm in clinical practice","volume":"10","author":"Cara","year":"2004","journal-title":"Med Sci Monit"},{"key":"2021120808113534200_cei13015-bib-0008","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF02220605","article-title":"The clinical pharmacology of 6-mercaptopurine","volume":"43","author":"Lennard","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"2021120808113534200_cei13015-bib-0009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756285614560733","article-title":"Towards the implementation of \u2018no evidence of disease activity\u2019 in multiple sclerosis treatment: the multiple sclerosis decision model","volume":"8","author":"Stangel","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"2021120808113534200_cei13015-bib-0010","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/00043426-200411000-00006","article-title":"Immunophenotype of blood lymphocytes in neuroblastoma-associated opsoclonus-myoclonus","volume":"26","author":"Pranzatelli","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"2021120808113534200_cei13015-bib-0011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/cyto.b.20542","article-title":"Central memory CD4+ T cells dominate the normal cerebrospinal fluid","volume":"80","author":"De Graaf","year":"2011","journal-title":"Cytometry B Clin Cytom"},{"key":"2021120808113534200_cei13015-bib-0012","first-page":"543","article-title":"An innovative approach to the problem of sedating children with opsoclonus\u2013myoclonus syndrome: effect on myoclonus and CSF monoamine metabolites","volume":"36","author":"Tate","year":"1994","journal-title":"Ann Neurol"},{"key":"2021120808113534200_cei13015-bib-0013","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.clpt.2003.12.001","article-title":"Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity","volume":"75","author":"Nygaard","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"2021120808113534200_cei13015-bib-0014","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0168-8278(02)00214-3","article-title":"Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis","volume":"37","author":"Langley","year":"2002","journal-title":"J Hepatol"},{"key":"2021120808113534200_cei13015-bib-0015","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00002826-200111000-00007","article-title":"A controlled pilot study of piracetam for pediatric opsoclonus-myoclonus","volume":"24","author":"Pranzatelli","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"2021120808113534200_cei13015-bib-0016","first-page":"S90","article-title":"Cyclophosphamide therapy in pediatric opsoclonus-myoclonus","volume":"58","author":"Pranzatelli","year":"2005","journal-title":"Ann Neurol"},{"key":"2021120808113534200_cei13015-bib-0017","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nri1130","article-title":"Three or more routes for leukocyte migration into the central nervous system","volume":"3","author":"Ransohoff","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"2021120808113534200_cei13015-bib-0018","first-page":"R147","article-title":"Kinetic model for disposition of 6-mercaptopurine in monkey plasma and cerebrospinal fluid","volume":"248","author":"Covell","year":"1985","journal-title":"Am J Physiol"},{"key":"2021120808113534200_cei13015-bib-0019","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0024-3205(99)00637-2","article-title":"Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood brain barrier","volume":"66","author":"Deguchi","year":"2000","journal-title":"Life Sci"},{"key":"2021120808113534200_cei13015-bib-0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1006\/smim.1999.0168","article-title":"Leukocyte traffic in the central nervous system: the participants and their roles","volume":"11","author":"Hickey","year":"1999","journal-title":"Semin Immunol"},{"key":"2021120808113534200_cei13015-bib-0021","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1517\/14712598.4.12.1887","article-title":"Th1\/Th2 cells in inflammatory disease states: therapeutic implications","volume":"4","author":"Moss","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"2021120808113534200_cei13015-bib-0022","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/0883073808324217","article-title":"Insights on chronic-relapsing opsoclonus\u2013myoclonus from a pilot study of mycophenolate mofetil","volume":"24","author":"Pranzatelli","year":"2009","journal-title":"J Child Neurol"},{"key":"2021120808113534200_cei13015-bib-0023","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/BF00915512","article-title":"The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease","volume":"5","author":"Brogan","year":"1985","journal-title":"J Clin Immunol"},{"key":"2021120808113534200_cei13015-bib-0024","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/cei.12580","article-title":"Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis","volume":"180","author":"Rodr\u00edguez-Martin","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"2021120808113534200_cei13015-bib-0025","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1258\/0004563041201455","article-title":"Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?","volume":"41","author":"Sanderson","year":"2004","journal-title":"Ann Clin Biochem"},{"key":"2021120808113534200_cei13015-bib-0026","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00007691-200404000-00024","article-title":"Analytic aspects of monitoring therapy with thiopurine medications","volume":"26","author":"Armstrong","year":"2004","journal-title":"Ther Drug Monit"},{"key":"2021120808113534200_cei13015-bib-0027","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00005176-200209000-00032","article-title":"Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report","volume":"35","author":"Rumbo","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2021120808113534200_cei13015-bib-0028","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/gut.2003.032896","article-title":"Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease","volume":"53","author":"Wright","year":"2004","journal-title":"Gut"},{"key":"2021120808113534200_cei13015-bib-0029","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/jpet.104.074815","article-title":"Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines","volume":"312","author":"Thomas","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"2021120808113534200_cei13015-bib-0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12974-016-0543-5","article-title":"6-Mercaptopurine attenuates tumor necrosis factor-\u03b1 production in microglia through Nur77-mediated transrepression and PI3K\/Akt\/mTOR signaling-mediated translational regulation","volume":"13","author":"Huang","year":"2016","journal-title":"J Neuroinflammation"},{"key":"2021120808113534200_cei13015-bib-0031","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1161\/ATVBAHA.110.205674","article-title":"6-mercaptopurine inhibits atherosclerosis in apolipoprotein E*3-Leiden transgenic mice through atheroprotective actions on monocytes and macrophages","volume":"30","author":"Pols","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2021120808113534200_cei13015-bib-0032","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00701-010-0608-7","article-title":"6-Mercaptopurine exerts an immunomodulatory and neuroprotective effect on permanent focal cerebral occlusion in rats","volume":"152","author":"Chang","year":"2010","journal-title":"Acta Neurochir (Wien)"},{"key":"2021120808113534200_cei13015-bib-0033","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0026-895X(24)13482-7","article-title":"6-Mercaptopurine decreases the Bcl-2\/Bax ratio and induces apoptosis in activated splenic B lymphocytes","volume":"51","author":"Hortelano","year":"1997","journal-title":"Mol Pharmacol"},{"key":"2021120808113534200_cei13015-bib-0034","doi-asserted-by":"crossref","first-page":"24791","DOI":"10.1074\/jbc.M302167200","article-title":"Identification of the antineoplastic agent 6-mercaptopurine as an activator of the orphan nuclear hormone receptor Nurr1","volume":"278","author":"Ordentlich","year":"2003","journal-title":"J Biol Chem"},{"key":"2021120808113534200_cei13015-bib-0035","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1677\/jme.1.01739","article-title":"TRAP220 is modulated by the antineoplastic agent 6-Mercaptopurine, and mediates the activation of the NR4A subgroup of nuclear receptors","volume":"34","author":"Wansa","year":"2005","journal-title":"J Mol Endocrinol"},{"key":"2021120808113534200_cei13015-bib-0036","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"J Clin Invest"},{"key":"2021120808113534200_cei13015-bib-0037","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.4049\/jimmunol.1302527","article-title":"Inhibition of GTPase Rac1 in endothelium by 6-mercaptopurine results in immunosuppression in nonimmune cells: new target for an old drug","volume":"192","author":"Marinkovi\u0107","year":"2014","journal-title":"J Immunol"},{"key":"2021120808113534200_cei13015-bib-0038","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/08880018609031198","article-title":"Plasma and erythrocyte concentrations of mercaptopurine after oral administration in children","volume":"3","author":"L\u00f6nnerholm","year":"1986","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.13015","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/190\/2\/217\/41644007\/cei13015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/190\/2\/217\/41644007\/cei13015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T23:28:03Z","timestamp":1750634883000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/190\/2\/217\/6412354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,7]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,8,7]]},"published-print":{"date-parts":[[2017,10,6]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.13015","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,11]]},"published":{"date-parts":[[2017,8,7]]}}}